TY - JOUR
T1 - Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13
T2 - The pneumococcal serotype replacement and distribution estimation (PSERENADE) project
AU - PSERENADE Team
AU - Knoll, Maria Deloria
AU - Bennett, Julia C.
AU - Quesada, Maria Garcia
AU - Kagucia, Eunice W.
AU - Peterson, Meagan E.
AU - Feikin, Daniel R.
AU - Cohen, Adam L.
AU - Hetrich, Marissa K.
AU - Yang, Yangyupei
AU - Sinkevitch, Jenna N.
AU - Ampofo, Krow
AU - Aukes, Laurie
AU - Bacci, Sabrina
AU - Bigogo, Godfrey
AU - Brandileone, Maria Cristina C.
AU - Bruce, Michael G.
AU - Camilli, Romina
AU - Castilla, Jesús
AU - Chan, Guanhao
AU - Chacón, Grettel Chanto
AU - Ciruela, Pilar
AU - Cook, Heather
AU - Corcoran, Mary
AU - Dagan, Ron
AU - Danis, Kostas
AU - de Miguel, Sara
AU - De Wals, Philippe
AU - Desmet, Stefanie
AU - Galloway, Yvonne
AU - Georgakopoulou, Theano
AU - Hammitt, Laura L.
AU - Hilty, Markus
AU - Ho, Pak Leung
AU - Jayasinghe, Sanjay
AU - Kellner, James D.
AU - Kleynhans, Jackie
AU - Knol, Mirjam J.
AU - Kozakova, Jana
AU - Kristinsson, Karl Gústaf
AU - Ladhani, Shamez N.
AU - Lara, Claudia S.
AU - León, Maria Eugenia
AU - Lepp, Tiia
AU - Mackenzie, Grant A.
AU - Mad’arová, Lucia
AU - McGeer, Allison
AU - Mungun, Tuya
AU - Mwenda, Jason M.
AU - Pekka Nuorti, J.
AU - Givon-Lavi, Noga
N1 - Publisher Copyright:
© 2021 by the authors.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
AB - Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
KW - Global
KW - Invasive pneumococcal disease
KW - Pneumococcal conjugate vaccines
KW - Pneumococcal meningitis
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85103083828&partnerID=8YFLogxK
U2 - 10.3390/microorganisms9040742
DO - 10.3390/microorganisms9040742
M3 - Article
AN - SCOPUS:85103083828
SN - 2076-2607
VL - 9
JO - Microorganisms
JF - Microorganisms
IS - 4
M1 - 742
ER -